Article

DNA nanoparticles successful in treating RP in mice

DNA compacted nanotechnology, a non-viral technology, has been used to rescue a murine model with retinitis pigmentosa with haploid insufficiency (referred to as retinal degeneration slow [RDS], said Muna Naash, PhD, of the Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City.

DNA compacted nanotechnology, a non-viral technology, has been used to rescue a murine model with retinitis pigmentosa with haploid insufficiency (referred to as retinal degeneration slow [RDS], said Muna Naash, PhD, of the Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City.

In their study, investigators combined the nanoparticles with DNA and injected the nanoparticles subretinally. They used 8- to 11-nanometer acetate particles to test the level of expression in the retinas of adult mice.

Dr. Naash and her colleagues found "enormous expression" in the retina and pigment epithelium in this animal model. Testing of the functional recovery after the subretinal injection indicated that 1 month later the electroretinography results for the rods and cones recovered, indicating that the nanoparticles are nontoxic. Importantly, expression was present up to 120 days post-injection. In newborn animals, there also was full recovery of the rods and cones.

This RDS model has about a 70% reduction in the rod a-wave and about a 40% reduction in the cone b-wave in animals aged 7 months. Dr. Naash reported that functional improvement was seen in the rod a-wave and a four-fold increase in the scotopic a-wave. The improvement was found to decrease over time. In adult animals, investigators also saw high expression levels (three-fold compared with uninjected eyes) with expression seen in almost all photoreceptor cells and functional improvements in the scotopic a-waves and photopic b-waves.

"Compacted DNA nanoparticles are effective in a nonviral delivery method," Dr. Naash said. "They are highly effective in transfected dividing and nondividing cells. The nanoparticles can target multiple ocular cell types and mediate high levels of gene expression up to 120 days after injection.

"Finally, this technology can rescue functionally and structurally the phenotype in the RDS model," she concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
© 2025 MJH Life Sciences

All rights reserved.